Table 1 Baseline characteristics of plasmablastic lymphoma patients from the Kamuzu Central Hospital Lymphoma Cohort study
Total (n = 12) | HIV+ (n = 6) | HIV- (n = 6) | |
|---|---|---|---|
Age, years, median (range) | 46 (26–71) | 39 (30–60) | 53 (26–71) |
Male sex, n (%) | 7 (58) | 2 (33) | 5 (83) |
Largest tumor location head and neck, n (%) | 12 (100) | 6 (100) | 6 (100) |
CNS involvement, n (%) | 1 (8) | 0 (0) | 1 (17) |
Bone marrow involvement, n (%) | 3 (25) | 2 (33) | 1 (17) |
Largest diameter of mass, cm, median (range) | 10 (3–22) | 8 (3–15) | 11 (10–22) |
Ann Arbor stage I/II, n (%) | 9 (75) | 6 (100) | 3 (50) |
Performance score ≥ 2, n (%) | 1 (8) | 0 (0) | 1 (17) |
White blood cells, 103/uL, median (range) | 4.6 (2.7–14.9) | 11.6 (6.2–12.5) | 6.1 (2.7–14.9) |
Absolute neutrophils, 103/uL, median (range) | 2.74 (0.92–10.6) | 2.55 (0.9–4.07) | 2.48 (1.3–10.6) |
Hemoglobin, g/dL, median (range) | 11 (6.2–14.9) | 11.6 (6.2–12.5) | 10.9 (10.1–14.9) |
Platelets, 103/uL, median (range) | 206 (103–666) | 210 (176–666) | 233 (103–458) |
Lactate dehydrogenase (LDH), IU/L, median (range)a | 338 (186–2522) | 328 (240–2522) | 226 (186–1803) |
CD4 count, cells/μL, median (range) | ― | 147 (9–460) | ― |
HIV RNA < 400 copies/mL, n (%) | ― | 3 (50) | ― |
EBER expression n (%) | 5 (71) | 3 (100) | 2 (50) |